Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Mar 18;59(6):1338–1348. doi: 10.2337/db09-1324

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2010 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 1. — Chronic rapamycin treatment decreases adiposity. Sprague-Dawley rats were treated with vehicle or rapamycin (2 mg/kg/day) for 15 days. A: Relative retroperitoneal fat weight. Total DNA tissue content and adipocyte diameter (μm) (B) and representative images of retroperitoneal fat (C) from control and rapamycin-treated rats (magnification ×10) D: Representative Western blots of adipose tissue lysates are shown for phosphorylated S6 (Ser240/244), Akt (Ser473 and Thr308), GSK-3α/β (Ser21/9), and total proteins (two representative animals of six). The graphs depict densitometric analysis of normalization of phospho-Akt/Akt protein. E: Adipose tissue proteins (500 μg) were immunoprecipitated with total Akt antibody. Immunoprecipitates were analyzed for Akt activity. The graphs depict densitometric analysis of total Akt activity. n = 6 for each group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. CTRL, control; RAP, rapamycin.